The main outcomes were the effective rate, left ventricular ejection fraction (LVEF), blood pressure, heart rate, cardiac index, stroke volume (SV), brain natriuretic peptide (BNP), hypersensitive C-reactive protein (Hs-CRP), left ventricular end diastolic volume (LVEDV), left ventricular end diastolic diameter (LVEDD), and adverse events (AEs).<h4>Results</h4>A total of 17 trials met the qualification criteria, which included 1,717 patients with heart failure. The gene discussed is CRP; the disease is heart failure.